Search Within

Michael Andrew Postow

  1. "Survivorship Research"
Formats
  1. Journal Article (40)
  2. Meeting Abstract (26)
  3. Research Letter (2)
  4. Book Section (1)
  5. Miscellaneous (1)
  6. Review (1)
Groups
  1. Department of Medicine (71)
  2. Melanoma Disease Management Team (71)
  3. Melanoma and Immunotherapeutics Service (71)
  4. Solid Tumor Oncology Division (71)
  5. Survivorship Research (71)
  6. Hematologic Malignancies, Division of (47)

More Groups

People
  1. Jedd Wolchok (40)
  2. Alexander Shoushtari (39)
  3. Margaret Callahan (38)
  4. Parisa Momtaz (36)
  5. Katherine Panageas (34)
  6. Paul Chapman (33)

More People

Years
  1. 2025 (2)
  2. 2024 (7)
  3. 2023 (4)
  4. 2022 (3)
  5. 2021 (6)
  6. 2020 (9)

More Years

Publications
  1. Journal of Clinical Oncology (26)
  2. Annals of Surgical Oncology (6)
  3. Clinical Cancer Research (3)
  4. The Oncologist (3)
  5. JAMA Oncology (2)
  6. Journal for ImmunoTherapy of Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (27)
  2. Springer (7)
  3. American Association for Cancer Research (4)
  4. Oxford University Press (4)
  5. Wiley Blackwell (4)
  6. American Medical Association (3)

More Publishers

Results (71)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intracranial outcomes of ipilimumab and nivolumab in melanoma brain metastases after progression on anti-PD-1 therapy
    Research Letter

    Lochrin, S. E.; Kalvin, H. L.; Smithy, J. W.; Chen, M. F.; Momtaz, P.; Shoushtari, A. N.; Panageas, K. S.; Postow, M. A.
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Randomized clinical trial of a digital integrative medicine intervention among patients undergoing active cancer treatment
    Journal Article

    Mao, J. J.; Bryl, K.; Gillespie, E. F.; Green, A.; Hung, T. K. W.; Baser, R.; Panageas, K.; Postow, M. A.; Daly, B.
    npj Digital Medicine (2025)

    Fulltext@MSK | Save
  • Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab
    Journal Article

    Lochrin, S. E.; Buonocore, D. J.; Young, R. J.; Kaley, T. J.; Postow, M. A.; Wolchok, J. D.; Shoushtari, A. N.; Momtaz, P.; Betof Warner, A. S.; Callahan, M. K.
    Pigment Cell & Melanoma Research (2024)

    Fulltext@MSK | Save
  • Fertility outcomes post immune checkpoint inhibitor exposure
    Research Letter

    Harrold, E. C.; Ogle, M.; O'Brien, E.; Wilde, C.; Sinopoli, J.; Weiss, J.; Martino, L.; Casson, A.; Kang, H. J.; Postow, M.; more...
    Cancer Cell (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma
    Meeting Abstract

    Smithy, J. W.; Momtaz, P.; Shoushtari, A. N.; Das, J. P.; Lezcano, C.; Nair, S.; Lochrin, S. E.; Chen, M. F.; Panageas, K.; Postow, M. A.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Intracranial outcomes with ipilimumab and nivolumab in melanoma brain metastases following progression on anti-PD-1 therapy
    Meeting Abstract

    Lochrin, S. E.; Kalvin, H. L.; Smithy, J. W.; Momtaz, P.; Shoushtari, A. N.; Panageas, K.; Postow, M. A.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Germline pathogenic variants in a large convenience cohort of multiple melanoma subtypes
    Meeting Abstract

    Lochrin, S. E.; Kemel, Y.; Stuart, J.; Smithy, J. W.; Mandelker, D.; Momtaz, P.; Chatila, W. K.; Schultz, N.; Postow, M. A.; Stadler, Z. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Acute care and overall survival results of a randomized trial of a virtual health intervention during routine cancer treatment
    Meeting Abstract

    Daly, R. M.; Bryl, K.; Baser, R. E.; Green, A.; Hung, T.; Gillespie, E. F.; Panageas, K.; Postow, M. A.; Mao, J. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Early on-treatment assessment of T cells, cytokines, and tumor DNA with adaptively dosed nivolumab + ipilimumab: Final results from the phase 2 ADAPT-IT study
    Journal Article

    Smithy, J. W.; Kalvin, H. L.; Ehrich, F. D.; Shah, R.; Adamow, M.; Raber, V.; Maher, C. A.; Kleman, J.; McIntyre, D. A. G.; Shoushtari, A. N.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Fertility post immune checkpoint blockade
    Meeting Abstract

    Ogle, M.; Harrold, E.; O'Brien, E.; Weiss, J. A.; Yaqubie, A.; Sinopoli, J. C.; Postow, M. A.; Cercek, A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save